Cimetidine and metoclopramide in oesophageal reflux disease
Although cimetidine is effective in oesophageal reflux disease,' it is not as consistently useful as in peptic ulceration. Metoclopramide increases lower oesophageal sphincter pressure in normal subjects2 and patients with reflux: and speeds gastric emptying.4 These properties together with the acid lowering effect of cimetidine appeared to provide a sound rationale for combination therapy.
Patients, methods, and results
Seventy six patients with symptoms of oesophageal reflux entered a multicentre study. They were allocated at random to 12 weeks' treatment with cimetidine 400 mg three times daily with meals and at bedtime, with or without metoclopramide 10 mg three times daily with meals. All patients were supplied with Rennies as required for symptomatic relief. The double dummy technique was used to ensure that the study was double blind. Symptomatic and endoscopic assessment was carried out at the start of the study, symptoms were reassessed at 2, 4, 8, and 12 weeks, and a further endoscopy performed after 12 weeks. Grading, according to the endoscopic appearance of the oesophageal mucosa, was as follows: 0=-normal, 1-friability, 2= discrete lesions (erosions or multiple superficial ulcers), 3-confluent and longitudinal lesions, 4 circinate ulceration with or without complications. Endoscopic improvement was defined as a decrease of two grades or more at the second endoscopy compared with the first. Differences between the two treatments were analysed by Z2 tests and p accepted as significant at the 5", level.
Three patients were excluded from the analysis for deviating from the protocol; of the remainder, 40 received cimetidine alone and 33 the combination. The groups were well matched for age, sex, duration of disease, smoking, and alcohol consumption. The cimetidine group, however, contained significantly more patients with stenosis (6 v 0, p < 0-05). The two treatments did not differ in their relief of symptoms or effect on antacid consumption, although there was a non-significant trend towards decreased antacid consumption in patients taking the combination. The rapid relief of heartburn is illustrated in the figure, some two thirds of the patients becoming symptom free within the first week. Eighteen of the 33 patients receiving cimetidine (55") had healed or improved oesophagitis at the end of the trial compared with eight of 19 (42%(,) taking the combination (not significant).
A total of 32 adverse reactions were reported in 22 of the patients receiving the combination, while 16 patients receiving cimetidine alone reported 22 adverse events. Of these patients, 11 receiving the combination were withdrawn compared with three taking cimetidine (p< 001). Reasons for withdrawal of the 11 patients in the combination treatment group were vomiting and dizziness; somnolence (two cases); lethargy; nervousness and clumsiness; diarrhoea and lethargy; lethargy and depression; weakness, lethargy, and exhaustion; feeling of choking; "thick" speech and strange bodily sensation; and water brash and worsening of the stricture. The three patients in the cimetidine group were withdrawn complaining of epigastric pain, depression, and drowsiness and vomiting, respectively.
Comment
Although the effect on symptoms was comparable, the combination of metoclopramide and cimetidine appeared less effective in this study in producing endoscopic improvement and healing than cimetidine alone, although this difference did not reach statistical significance. A possible explanation might be that metoclopramide reduced the bioavailability of cimetidine.5 In our study adverse effects were certainly more common in patients receiving the combination and severe enough to necessitate withdrawal in one third. The results therefore suggest that, despite the plausible pharmacological rationale, there is no clinical advantage in coprescribing cimetidine and metoclopramide for oesophageal acid reflux disease. 
Serum ferritin concentration in Gaucher's disease
The serum ferritin concentration is widely used as a measure of body iron stores but is inappropriately raised in liver disease and in chronic inflammatory and malignant diseases. We report finding raised serum ferritin concentrations in patients with Gaucher's disease.
Patients, methods, and results
We studied seven patients with type I Gaucher's disease. Serum ferritin was estimated by the immunoradiometric assay previously used in this laboratory. The proportion of glycosylated ferritin was estimated by the concanavalin A binding technique. Unsaturated transcobalamin II concentration was measured by radioactive vitamin B,2 binding and Quso G32 separation.' A standard desferrioxamine 24 hour urine excretion test was performed in two patients using an intramuscular dose of 10 mg desferrioxamine/kg body weight. Other haematological and biochemical measurements were by standard techniques. The table lists the clinical, haematological, and biochemical findings. None of the patients had received previous blood transfusions or, so far as we could ascertain, iron therapy.
Six of the seven patients showed raised serum ferritin concentrations. These bore no relation to the sex of the patient, size of the spleen or liver, blood count, extent of bone lesions, serum acid phosphatase activity, serum aspartate transaminase activity, or concentration of serum vitamin B,2 or unsaturated transcobalamin II. The transcobalamin II concentration was raised in all six patients studied. Interestingly, however, the two youngest patients showed the lowest serum ferritin values. The proportion of serum ferritin bound by concanavalin A, measured in five patients, ranged from 38°,, to 55" (within the normal range). The 24 hour urinary iron excretion after intramuscular desferrioxamine was normal in both patients tested (table) .
Comment
Gaucher's disease is an inborn error of metabolism due to deficiency of a lysosomal enzyme, ,!-glucosidase, resulting in accumulation of glucocerebroside in large macrophages throughout the reticuloendothelial system. We found raised serum ferritin concentrations in six of seven patients with type I Gaucher's disease. This could not be attributed to iron overload as the urinary iron excretion after intramuscular desferrioxamine, estimated in two patients (cases 2 and 4) with a 10-fold increase in serum ferritin concentrations, was not increased. Other studies have found raised serum acid phosphatase activities and transcobalamin II concentrations in Gaucher's disease.2 Acid phosphatase is a lysosomal enzyme present in Gaucher's cells and transcobalamin II is synthesised by macrophages.3 Increased iron has been detected within the macrophages in Gaucher's disease.4 The iron is dispersed within the cells as individual micelles of ferritin.5 Probably raised serum ferritin concentrations in patients with Gaucher's disease result from excessive release of ferritin from the large macrophages (Gaucher's cells). Our results suggest that serum ferritin increases with age in Gaucher's disease, but a much larger study would be necessary to prove this. At all events, Gaucher's disease can be added to the list of conditions in which the serum ferritin value may be inappropriately high in relation to body iron stores. 
